Stock in the Spotlight: InflaRx N.V. (NASDAQ: IFRX)

The long-term trend of the EPS is a vital number as it helps understand the future potential of InflaRx N.V.. I will do my best to analyze this stock, but there is limited information, therefore please check back later by doing a search here or going to the tag page for the stock symbol IFRX here. EPS growth is a vital measure of execution of the strategy for InflaRx N.V. since it indicates how well the business is allocating resources to benefit shareholders.

InflaRx N.V. is part of the biotechnology industry and is in the healthcare sector. The company CEO is Niels Riedemann. InflaRx NV is a biopharmaceutical company. It discovers and develops potent and specific inhibitors of the complement activation factor known as C5a.

Previous Intraday Performance:

The IFRX shares had a previous change of -0.15% which opened at 34.08 and closed at 33.60. It moved to an intraday high of 34.98 and a low of 33.01.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Historical Performance:

Over the last five trading days, IFRX shares returned -0.74% and in the past 30 trading days it returned -7.62%. Over three months, it changed 10.82%. In one year it has changed 20.65% and within that year its 52-week high was 42.83 and its 52-week low was 20.31. IFRX stock is 65.44% above its 52 Week Low.

Our calculations result in a 200 day moving average of 32.86 and a 50 day moving average of 31.84. Right now, IFRX stock is trading 2.27% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa


The company has a market cap of $871.5m with 25.9m shares outstanding and a float of 25.9m shares. Trading volume was 186,906 shares and has experienced an average volume of 63,707 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for InflaRx N.V. was -3.12 which ended on 31st of December 2017. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.44.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.31
06-30-2018:  -0.12
03-31-2018:  -0.49

Indicators Also to Watch:

Based on the latest filings, there is 58.30% of institutional ownership.

I calculated the beta to be -0.94

SeekingAlpha:  MSG Networks misses by $0.07, beats on revenue

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -51.05%, return on assets is -33.13% and price-to-book is 4.86.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Tags: , , ,

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *